Call for abstracts

Call for abstracts

Application Period: from noon on February 15, 2023
to noon on April 19, 2023 (JST/GMT+9)

to noon on May 9, 2023(JST/GMT+9)

Thank you for your submission!
Abstract Submission is closed.

Foreign presenters and Co-speakers do not have to be members of the Japanese Association for Thoracic Surgery (JATS)

*For those who are interested in becoming JATS members, please contact the Japanese Association for Thoracic Surgery:
1F Teral Koraku Building, 2-3-27 Koraku, Bunkyo-ku, Tokyo 112-0004, JAPAN
Phone: +81-3-3812-4253 Fax: +81-3-3816-4560
URL: E-mail:

If you are interested in submitting an abstract for a Primary Session,
please click on the Guideline button below for details and check if you are eligible for the 7th JATS Asian Travelling Fellowship!

Click here! ↓

The 7th JATS Asian Travelling Fellowship Application Guidelines Application Form

1.Presentations must be of original material and being presented for the first time.

2.Once presentations are approved by the Program Committee, Copyright of the presentations will be assumed by the Japanese Association for Thoracic Surgery.

3.Application procedure

1- Application period

Opens at noon on February 15, 2023 (JST/GMT+9)
Closes at noon on April 19, 2023 (JST/GMT+9)

2- Submissions

1. Recommended Browsers

To use the online abstract submission system, please use the latest version of Firefox, Google Chrome, Microsoft Edge or Safari.

*Internet Explorer (IE) or any other browsers are non-compliant browsers for the online abstract submission system.

2. Abstract Submission Number and Password

During the course of entering your information, you will be required to set your own password.
Upon completion of the abstract submission process, you will be given your abstract submission number. Your abstract submission number and password are very important, so please keep them safe and confidential.
We, the Program Secretariat, will use the abstract submission number when contacting you.
Please note, we will not respond to inquiries regarding security issues. Your abstract submission number and password may be used to login and modify your abstract and information up until the submission deadline (at noon on April 19, 2023, JST/GMT+9).

3. Abstract Specifications

Language: English
Abstract Title: Limited to 200 characters
Abstract Text: Limited to 2,000 characters
Figures and Tables: A single GIF or JPEG file no larger than 300KB

(portrait or landscape accepted; size will be reduced to approximately 6*4 cm).

4. Confirmation of Submission

After submitting your abstract, you will receive a confirmation e-mail. You may use the submission link to view and modify your abstract at any time up until the abstract submission deadline.
If you do not receive confirmation by e-mail, please contact the Program Secretariat:

5. Notification of Acceptance

The Program committee will carefully review all submitted abstracts, consider the reviews, and then make a final decision on which papers to select.
The first author will receive a notification of acceptance via email by the end of July.
The paper selection results will also be listed on the congress website.
Following the notification of acceptance, the first author must register for the 76th Annual Meeting, and abstracts can only be presented upon receipt of the registration fee.

6. Video Submission

For those presenting in Video Symposiums, Video Workshops, Video Clinics, and Clinical Video Sessions, please place a check mark “✔” under the “video” when submitting your abstract.
Once completing the abstract submission process, please return to the “Call for Abstracts” page to upload your video for review. Click on the “Upload Video” button to the appropriate session type to complete the video upload process. In this process, you are required to enter your “Abstract submission number”, so please retain your number.

Video Submission

Modify and Delete

●Primary Session

E. Esophagus
06_Video Symposium
Feasibility and safety of minimally invasive approach for locally advanced cT3br or cT4 esophageal cancer

Clinical Question/Outline

CQ1:Can MIE be performed safely in patients with locally advanced esophageal cancer?

CQ2:Is MIE feasible in curability as compared with open esophagectomy?

Open surgery has been the standard approach for esophagectomy for patients with cT3br or T4 locally advanced esophageal cancer after neoadjuvant or induction therapy. Recently, minimally invasive esophagectomy (MIE) became an alternative approach for such cases in some institutes. However, it remains unclear if MIE can be performed safely, whether a plan for conversion to open surgery is required, and whether MIE guarantees curability equivalent to open surgery. In this video symposium, please discuss the feasibility and efficacy of MIE for locally advanced esophageal cancer compared with open surgery.

●Oral/Poster Presentation, Clinical Video Session

  • T. Cross-disciplinary
  • 01 T-1 Cross-disciplinary/Combined cardiothoracic surgery (heart/aorta+α)
    02 T-2 Cross-disciplinary/Combined cardiothoracic surgery (lung+α)
    03 T-3 Cross-disciplinary/Combined cardiothoracic surgery (esophagus+α)
  • H. Heart
  • 04 H-1 Heart/Valvular disease-aortic
    05 H-2 Heart/Valvular disease-mitral
    06 H-3 Heart/Valvular disease-tricuspid
    07 H-4 Heart/Valvular disease-pulmonary
    08 H-5 Heart/Valvular disease-combined
    09 H-6 Heart/Valvular disease-MICS/Robotics
    10 H-7 Heart/Valvular disease-TAVI/MitraClip
    11 H-8 Heart/Valvular disease-infective endocarditis
    12 H-9 Heart/Valvular disease-others
    13 H-10 Heart/Ischemic heart disease-CABG
    14 H-11 Heart/Ischemic heart disease-minimally invasive CABG
    15 H-12 Heart/Ischemic heart disease-complications of myocardial infarction
    16 H-13 Heart/Ischemic heart disease-others
    17 H-14 Heart/Aorta-type A dissection
    18 H-15 Heart/Aorta-type B dissection
    19 H-16 Heart/Aorta-complications of aortic dissection
    20 H-17 Heart/Aorta-aortic root
    21 H-18 Heart/Aorta-ascending/arch
    22 H-19 Heart/Aorta-descending
    23 H-20 Heart/Aorta-thoracoabdominal
    24 H-21 Heart/Aorta-esophageal/bronchial fistula
    25 H-22 Heart/Aorta-infected aneurysm/graft infection
    26 H-23 Heart/Aorta-others
    27 H-24 Heart/Combined surgery (valve, coronary, aorta, etc.)
    28 H-25 Heart/Arrhythmia/pacemaker
    29 H-26 Heart/Maze surgery
    30 H-27 Heart/Closure/resection of LAA
    31 H-28 Heart/Acyanotic congenital heart disease
    32 H-29 Heart/Aortic arch anomaly/coarctation of aorta
    33 H-30 Heart/Hypoplastic left heart syndrome: HLHS
    34 H-31 Heart/Transposition of great arteries
    35 H-32 Heart/Miscellaneous cyanotic diseases
    36 H-33 Heart/Long-term issues/complications
    37 H-34 Heart/Adult congenital heart disease
    38 H-35 Heart/Cardiac tumor
    39 H-36 Heart/Cardiomyopathy/myocarditis
    40 H-37 Heart/Heart・heart-lung transplantation
    41 H-38 Heart/Myocardial protection and metabolism
    42 H-39 Heart/Extracorporeal circulation
    43 H-40 Heart/Mechanical circulatory support/ventricular assisted system
    44 H-41 Heart/Pulmonary circulation(CTEPH)
    45 H-42 Heart/Perioperative management and complications
    46 H-43 Heart/Examination and diagnosis
    47 H-44 Heart/Experiment
    48 H-45 Heart/New surgical techniques
    49 H-46 Heart/Development and innovation
    50 H-47 Heart/Regenerative medicine and tissue engineering
    51 H-48 Heart/Others
  • L. Lung
  • 52 L-1 Lung/Lung cancer
    53 L-2 Lung/Pulmonary metastasis
    54 L-3 Lung/Mediastinum (thymic disease)
    55 L-4 Lung/Mediastinum (non-thymic disease)
    56 L-5 Lung/Pleura, chest wall, and thorax
    57 L-6 Lung/Trachea and bronchus
    58 L-7 Lung/Pneumothorax and emphysematous/bullous lung disease
    59 L-8 Lung/Inflammatory lung diseases
    60 L-9 Lung/Benign lung tumor
    61 L-10 Lung/Pediatric lung disease
    62 L-11 Lung/Minimally invasive surgery
    (Video-assisted and Robot-assisted thoracic surgery, VATS and RATS)
    63 L-12 Lung/Salvage surgery
    64 L-13 Lung/Lung transplantation and assisted circulation
    65 L-14 Lung/New surgical techniques
    66 L-15 Lung/Perioperative management and complications
    67 L-16 Lung/Examination and diagnosis
    68 L-17 Lung/Gene and molecular biology
    69 L-18 Lung/Regenerative medicine
    70 L-19 Lung/Others
  • E. Esophagus
  • 71 E-1 Esophagus/Esophageal malignancies
    72 E-2 Esophagus/Esophageal benign diseases
    73 E-3 Esophagus/Barrett's esophagus and adenocarcinoma
    74 E-4 Esophagus/Esophagectomy and lymphadenectomy
    75 E-5 Esophagus/Esophageal reconstruction
    76 E-6 Esophagus/Minimally invasive and robotic-assisted surgery
    77 E-7 Esophagus/Treatment for recurrent esophageal cancer
    78 E-8 Esophagus/Aortoesophageal fistula
    79 E-9 Esophagus/Genetics and molecular biology
    80 E-10 Esophagus/Pathology and experimental research
    81 E-11 Esophagus/Perioperative management and complications
    82 E-12 Esophagus/Multidisciplinary treatment
    83 E-13 Esophagus/Palliative treatment
    84 E-14 Esophagus/Esophageal cancer in elderly
    85 E-15 Esophagus/Others
7- Presentation format

Information about presentation format and methodology requirements will be released in due course. These requirements are subject to change. Applicants are advised to check the website for the latest information.

Abstract Submission


Abstract Submission

Confirm, Modify and Delete


Abstract Submission

Confirm, Modify and Delete


Secretariat of the 76th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery c/o Congrès Inc.


page top